Friday, August 14, 2020
AGC Biologics, a global biopharmaceutical contract manufacturing and development organization (CDMO), announced its partnership with Ono Pharmaceutical Co., Ltd. (ONO) to carry out the manufacturing of New and innovative biopharmaceutical products in clinical development phase. ONO is an R&D-oriented pharmaceutical company committed to the discovery and development of innovative drugs.
"We are very excited to launch this partnership with ONO," explained Mark Womack , Head of Biology at AGC Biologics. "We can't wait to collaborate closely with ONO to launch the manufacture of important and innovative therapies."
AGC Biologics' worldwide network spans three continents, with cGMP compliant facilities in Seattle, Washington ; Boulder, Colorado ; Copenhagen, Denmark; Heidelberg, Germany; Milan and Bresso, Italy and Chiba , Japan. Best-in-class services include the development and manufacture of microbial and mammalian-based therapeutic proteins, plasmid DNA (pDNA), viral vectors, and genetically engineered cells.
